Skip to Main Content

Paper Details

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Br J Cancer
31
2014
COX-2, COX2, DCIS, ER, ER-positive, Ki-67, aromatase, celecoxib, ductal carcinoma in situ, ductal carcinoma in situ of the breast, exemestane, patients, tumours, women
Author NameAffiliation
Francesca M BuffaWeatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital
Siddhartha DebPeter MacCallum Cancer Centre, Melbourne University
Adrian L HarrisWeatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK [2] NIHR Oxford Biomedical Research Centre
Sunil R LakhaniThe University of Queensland, UQ Centre for Clinical Research, The Royal Brisbane and Women's Hospital
Sunil R LakhaniThe University of Queensland, UQ Centre for Clinical Research, The Royal Brisbane and Women's Hospital
  • 1 - 5

Datasets

Release 1.2